Literature DB >> 20704484

A subtype of a Pseudomonas aeruginosa cystic fibrosis epidemic strain exhibits enhanced virulence in a murine model of acute respiratory infection.

Melissa E K Carter1, Joanne L Fothergill, Martin J Walshaw, Kumar Rajakumar, Aras Kadioglu, Craig Winstanley.   

Abstract

BACKGROUND: The Liverpool epidemic strain (LES) of Pseudomonas aeruginosa is a particularly successful cystic fibrosis (CF) pathogen associated with transmissibility, increased patient morbidity, and, unusually, infection of the non-CF parents of a patient with CF.
METHODS: Using assays for virulence-associated exoproducts, biofilm formation, Caenorhabditis elegans killing, and a murine model of acute respiratory infection, we compared the pathogenic behavior of representatives of 4 subtypes of the LES, including LES431, an isolate associated with the infection of a parent without CF.
RESULTS: The quorum-sensing-defective lasR mutant LES400 produced less exoproduct and had less C. elegans killing activity than the other LES subtypes, which were represented by LES431, LESB58, and LESB65. LES431 was deficient in biofilm formation, compared with the other LES sub-types. The LES subtypes displayed a range of virulence in the mouse model, with LES431 being by far the most virulent. The genome-sequenced isolate LESB58, effective at establishing infections in a rat model of chronic infection, was the least virulent subtype in the murine acute infection model.
CONCLUSIONS: LES isolates display widely variable pathogenic characteristics. LES431, associated with transmission to the non-CF parent of a CF patient, represents a "hypervirulent" subtype more adapted to acute infections than chronic infections.

Entities:  

Mesh:

Year:  2010        PMID: 20704484     DOI: 10.1086/655781

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.

Authors:  Urszula Wnorowska; Katarzyna Niemirowicz; Melissa Myint; Scott L Diamond; Marta Wróblewska; Paul B Savage; Paul A Janmey; Robert Bucki
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Authors:  Joanne L Fothergill; Eilidh Mowat; Martin J Walshaw; Martin J Ledson; Chloe E James; Craig Winstanley
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

Review 3.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

Review 4.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

5.  Evolutionary genomics of epidemic and nonepidemic strains of Pseudomonas aeruginosa.

Authors:  Jeremy R Dettman; Nicolas Rodrigue; Shawn D Aaron; Rees Kassen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

6.  Developing an international Pseudomonas aeruginosa reference panel.

Authors:  Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley
Journal:  Microbiologyopen       Date:  2013-11-11       Impact factor: 3.139

7.  Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.

Authors:  Sebastian Kirchner; Joanne L Fothergill; Elli A Wright; Chloe E James; Eilidh Mowat; Craig Winstanley
Journal:  J Vis Exp       Date:  2012-06-05       Impact factor: 1.355

8.  Proteomic profiling of Pseudomonas aeruginosa AES-1R, PAO1 and PA14 reveals potential virulence determinants associated with a transmissible cystic fibrosis-associated strain.

Authors:  Nathan J Hare; Nestor Solis; Christopher Harmer; N Bishara Marzook; Barbara Rose; Colin Harbour; Ben Crossett; Jim Manos; Stuart J Cordwell
Journal:  BMC Microbiol       Date:  2012-01-22       Impact factor: 3.605

9.  Comparative genomics of isolates of a Pseudomonas aeruginosa epidemic strain associated with chronic lung infections of cystic fibrosis patients.

Authors:  Julie Jeukens; Brian Boyle; Irena Kukavica-Ibrulj; Myriam M Ouellet; Shawn D Aaron; Steve J Charette; Joanne L Fothergill; Nicholas P Tucker; Craig Winstanley; Roger C Levesque
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

10.  The B lymphocyte differentiation factor (BAFF) is expressed in the airways of children with CF and in lungs of mice infected with Pseudomonas aeruginosa.

Authors:  Daniel R Neill; Gemma L Saint; Laura Bricio-Moreno; Joanne L Fothergill; Kevin W Southern; Craig Winstanley; Stephen E Christmas; Joseph R Slupsky; Paul S McNamara; Aras Kadioglu; Brian F Flanagan
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.